News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 20, 2022
PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome...
-
Sep 19, 2022
Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks PrimeC showed a statistically...
-
Aug 31, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June...
-
Aug 2, 2022
- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at EverythingALS's Expert Talk Series on...
-
Jul 28, 2022
NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to...